Health AI Central
Share:
Peer-Reviewed Publication
Future Oncol2026;1-10.July 16, 2026Journal Article

US real-world biomarker testing differences and treatment choice in advanced ovarian cancer: results of a retrospective study.

John Nakayama1, Madeline Richey2, Khilna Patel2, John Hartman3, Zsofia Kiss4, Maureen Cooney5, Alin Kalayjian3,6, Jean A Hurteau7
1Division of Gynecologic Oncology, Allegheny Health Network, Pittsburgh, PA, USA.
2Flatiron Health, New York, NY, USA.
3GSK, Philadelphia, PA, USA.
4GSK, Munich, Germany.
5GSK, Durham, NC, USA.
6Penumbra, Inc, Alameda, CA, USA.
7GSK, Waltham, MA, USA.
PubMed DOI

Abstract

AIMS: Describe trends in real-world BRCA and homologous recombination deficiency (HRD) testing rates among patients with advanced epithelial ovarian cancer (EOC). METHODS: In this US-nationwide electronic health record-derived deidentified database study, eligible adult patients diagnosed with OC on/after 1 January 2016 had stage III/IV EOC at diagnosis, and initiated 1L platinum-based chemothera…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.